Л. В. Маснева
15 works · 45 citations · h-index 4
Top works
- Analysis of the state-of-the-art of consulting medical care to patients with glucocorticoid-induced osteoporosis or its risk according to the data of a questionnaire survey (GLUCOST study)
- Factors affecting the results of analgesic therapy. Results of the Russian multicentre study of NOTE (NSAID: Open-label Trial of Efficacy)
- RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA)
- PREVALENCE AND RISK FACTORS OF LOW-ENERGY SKELETAL FRACTURES IN PATIENTS WITH CHRONIC INFLAMMATORY DISEASES. THE RESULTS OF A MULTICENTER STUDY OF THE RUSSIAN ASSOCIATION ON OSTEOPOROSIS GLUKOST
- Evaluation of the efficacy and safety of a combination of chondroitin sulfate and glucosamine sulfate for knee and hip osteoarthritis in real clinical practice
- Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study
- Direct interleukin-6 blockade in real-world clinical practice – a path to rationalization of pharmacotherapy and control of rheumatoid arthritis
- Olokizumab effectively improved symptoms of rheumatoid arthritis in an open-label observational study
- Rheumatoid arthritis in real clinical practice: initiation of therapy with biological agents. Results of the «Computer Terminals of Self-Assessment for Patients with Rheumatic Diseases» («TERMINAL-II») project
- AB0598 Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results from A Russian Registry (NORMA)
- Оценка частоты и факторов риска низкоэнергетических переломов скелета по данным опроса вольных хроническими воспалительными заболеваниями. Результаты многоцентрового исследования Российской ассоциации по остеопорозу глюкост
- Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: Two-Year Results of the Real Word Evidence LIBRA Study
- Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: Two-year results of the real word evidence LIBRA study
- Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: First Year Results of the LIBRA Post-Registration Safety Study
- Эффективность, безопасность и удержание на терапии нетакимабом при лечении пациентов с анкилозирующим спондилитом в условиях реальной клинической практики: результаты первого года пострегистрационного исследования безопасности LIBRA